

Curriculum Vitae

Samira Fafi-Kremer, PharmD, PhD



Date of Birth March 15, 1972, Meknes, Morocco,
married, two childrens (4 years, 8 years)
French Nationality

Position

- Professor of Medicine – Attending Physician (PU-PH), University of Strasbourg and University Hospitals, Strasbourg
- Head of Molecular Microbiology Unit, University Hospitals, Strasbourg
- Coordinator of Translational Medicine Platform, Inserm Virology Unit U1110 (ex U748), University of Strasbourg

Appointments and Positions – Clinical

2013- Professor of Medicine – Attending Physician (PU-PH), Laboratoire de Virologie Médicale, Pôle de Biologie, Hopitaux Universitaires de Strasbourg

2011- Head of Molecular Microbiology Unit, University Hospitals, Strasbourg

2007-2013 Associate Professor of Medicine– Attending Physician (MCU-PH), Laboratoire de Virologie Médicale, Pôle de Biologie, Hopitaux Universitaires de Strasbourg

2005-2007 Resident (AHU), Laboratoire de Virologie Médicale, Pôle de Biologie, Hopitaux Universitaires de Strasbourg, France.

2001-2005 Resident (AHU), Laboratoire de Virologie Médicale, Hopitaux Universitaires de Grenoble, France.

1997-2001 Intern in “Pharmacie Spécialisée”, Faculty of Pharmacy, Joseph Fourier University, Grenoble, France

Appointments and Positions – Research

2011- Coordinator of Translational Medicine Platform, Inserm Virology Unit U1110, University of Strasbourg

2010- Research group leader, Inserm Virology Unit U1110, Labex “HEPSYS”, University of Strasbourg

2006-2009 Postdoc in Inserm Unit 748, “Virus-host interactions and liver disease”, University of Strasbourg (Head: T Baumert)

2001-2005 Doctoral student, Joseph Fourier University, Grenoble, France.

Education

2009 Habilitation, Faculty of Medicine, University of Strasbourg, France

2005 University Thesis, Speciality « Bio-Technologie Santé et Management », Joseph Fourier University, Grenoble.

2004 Diplôme Universitaire de Pédagogie Médicale, Faculté de Médecine, Grenoble

2001 Doctor of Pharmacy, DES Pharmacie Spécialisée, Joseph Fourier University, Grenoble, France

2000 Master research degree “Génie Biologique et Médical, Joseph Fourier University, Grenoble, France

1990-2001 University of Grenoble Pharmaceutical School

1989-1990 Faculty of Biology, Meknes, Morocco.

1989 Baccalauréat Section Sciences Expérimentales Bilingues, Morocco.

Medical Biology Certificates

2001 Board Certification in Virology (Grenoble, France)

1999 Board Certification in Hematology (Grenoble, France)

1998 Board Certification in Bacteriology (Grenoble, France)

1997 Board Certification in Medical Biochemistry (Grenoble, France)

1997 Board Certification in Clinical Pharmacy (Grenoble, France)

1997 Board Certification in Gestion et Droit Médical (Grenoble, France)

Teaching

Lectures and seminars in basic and medical virology:

- University of Strasbourg Medical School
- Master and PhD programs
- Postgraduate education medical doctors

Research supervision

- Thèses d'université (3 doctorants)
- Master 1 (13 étudiants) et Master 2 recherche (6 étudiants)

Reviewer for Scientific Journals

J. Clin. Virol., J. Virol., Vaccine, J. Hepatol.

Funding and contracts

ANRS, Paris; AAP RCT (DGOS-Inserm), Paris; API, Strasbourg; Hoffmann-La Roche Corp. Bâle, Suisse

Main publications

1. **Fafi-Kremer S**, Morand P, Brion JP, Pavese P, Baccard M, Germe R, Genoulaz O, Nicod S, Jolivet M, Ruigrok RW, Stahl JP, Seigneurin JM. Long-term shedding of infectious Epstein-Barr virus after infectious mononucleosis. *J. Infect. Dis.* 2005; 19:985-9. (IF= 6,28)
2. **Fafi-Kremer S**, Morand P, Germe R, Ballout M, Brion JP, Genoulaz O, Nicod S, Stahl JP, Ruigrok R, and Seigneurin JM. A Prospective follow-up of Epstein-Barr Virus LMP-1 genotypes in saliva and blood during infectious mononucleosis. *J. Infect. Dis.* 2005; 192:2108-11. (IF= 6,28)
3. Choquet S, Leblond V, Herbrecht R, Socie G, Stoppa AM, Vandenberghe P, Fischer A, Morschhauser F, Salles G, Feremans W, Vilmer E, Peraldi MN, Lang P, Lebranchu Y, Oksenhendler E, Garnier JL, Lamy T, Jaccard A, Ferrant A, Offner F, Hermine O, Moreau A, **Fafi-Kremer S**, Morand P, Chatenoud L, Berriot-Varoqueaux N, Bergougnoux C, Milpied N. Efficacy and safety of Rituximab in B-cell post-transplant lymphoproliferative disorders (B-PTLD): results of a prospective multicenter phase II study. *Blood*, 2006; 107:3053-7. (IF= 10,56)
4. Payan C, Pivert A, Morand P, **Fafi-Kremer S**, Carrat F, Pol S, Cacoub P, Perronne C, Lunel F, and the Scientific committee of ANRS HC02 RIBAVIC study. Early virological response in HIV/HCV co-infected patients to IFN or Peg-IFN plus Ribavirin assessed by HCV RNA. *Gut*, 2007; 56:1111-6. (IF= 10,61)
5. **Fafi-Kremer S**, Stoll-Keller F, Baumert TF. Efficient postexposure prophylaxis by hepatitis A vaccine. *Hepatology*, 2008; 47:1416-8. (IF= 10,89)
6. **Fafi-Kremer S**, Fofana I., Soulier E., Carolla P., Meuleman P., Leroux-Roels G., Patel A.H., Cosset F.L., Pessaux P., Doffoel M., Wolf P., Stoll-Keller F. and Baumert T. F. Escape from antibody-mediated neutralization and viral entry are key determinants for hepatitis C virus re-infection in liver transplantation. *J. Exp. Med.*, 2010; 207, 2019-31. (IF=14,77)
7. Keymeulen B, Candon S, **Fafi-Kremer S**, Ziegler A, Leruez-Ville M, Mathieu C, Vandemeulebroucke E, Walter M, Crenier L, Thervet E, Legendre C, Pierard D, Hale G, Waldmann H, Bach JF, Seigneurin JM, Pipeleers D, Chatenoud L. Transient Epstein Barr virus reactivation in CD3 monoclonal antibody-treated patients. *Blood*, 2010; 115:1145-55. (IF= 10,56)
8. Fofana I, Krieger S, Grunert F, Glaubien S, Xiao F, **Fafi-Kremer S**, Soulier E, Royer C, Thumann C, Mee CJ, McKeating JA, Dragic T, Pessaux P, Stoll-Keller F, Schuster C, Thompson J and Baumert TF. Monoclonal anti-claudin 1 antibodies prevent hepatitis C virus infection of primary human hepatocytes. *Gastroenterology*, 2010; 139:953-64, 964.e1-4. (IF= 12,03)
9. **Fafi-Kremer S**, Habersetzer F, Baumert TF. Hepatitis C virus entry and glucocorticosteroids. *J. Hepatol.*, 2010; 53: 1148-50. (IF= 9,33)
10. Zeisel M, Fofana I, **Fafi-Kremer S**, Baumert TF. Hepatitis C virus entry into hepatocytes: molecular mechanisms and targets for antiviral therapies. *J. Hepatol.*, 2011; 54:566-76. (IF= 9,33)
11. Lacek K*, Vercauteren K*, Grzyb K, Naddeo M Verhoye L, Slowikowski MP, **Fafi-Kremer S**, Patel AH, Baumert TF, Folgore A, Leroux-Roels G, Cortese R, Meuleman P, Nicosia A. Novel human SR-BI antibodies prevent infection and dissemination of HCV in vitro and in humanized mice. *J. Hepatol.*, 2012; 57:17-23. (IF= 9,33)
12. Fofana I*, **Fafi-Kremer S***, Carolla P*, Fauvelle C, Zahid MN, Turek M, Heydmann L, Cury K, Combet C, Hayer J, Cosset FL, Pietschmann T, Hiet MS, Bartenslager R, Habersetzer F, Doffoel M, Keck ZY, Fong SKH, Zeisel MB, Stoll-Keller F, Baumert TF. (*: Equally contributed). Mutations that alter use of hepatitis C virus cell entry factors mediate escape from neutralizing antibodies. *Gastroenterology*, 2012; 143:223-233. (IF= 12,03)
13. Lambotin M, Barth H, Moog C, Habersetzer F, Baumert TF, Stoll-Keller F, **Fafi-Kremer S**. Challenges for HCV vaccine developments in HIV-HCV coinfection. *Expert Review of Vaccines*, 2012; 11:791-804. (IF=4,21)
14. Schvoerer E, Moenne-Loccoz R, Murray JM, Velay A, Turek M, Fofana I, **Fafi-Kremer S**, Erba AC, Habersetzer F, Doffoel M, Gut JP, Donlin MJ, Tavis JE, Zeisel MB, Stoll-Keller F, Baumert TF. Hepatitis C virus envelope glycoprotein signatures are associated with treatment failure and modulation of viral entry and neutralization. *J. Infect. Dis.*, 2013; 207:1306-15. (IF= 6,28)
15. Lepiller Q, Barth H, Lefebvre F, Herbrecht R, Lutz P, Kessler R, **Fafi-Kremer S**, Stoll-Keller F. High incidence but low burden of coronaviruses and preferential associations between respiratory viruses. *J. Clin. Microbiol.*, 2013; 51:3039-46. (IF=4,06)